CDKN1A
CDKN1A (Cyclin-dependent kinase inhibitor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Hepatocellular carcinoma, Colorectal cancer and 4 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Plays an important role in controlling cell cycle progression and DNA damage-induced G2 arrest. Involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage. Also involved in p53-independent DNA damage-induced G2 arrest mediated by CREB3L1 in astrocytes and osteoblasts. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localisation and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex. Location: Cytoplasm; Nucleus (UniProt). Locus 6p21.2 (HGNC).
- Bladder & urothelial cancer: Open Targets association 0.64 with urinary bladder cancer (MONDO_0001187); IntOGen driver in 5 cohorts (BLCA)
- Hepatocellular carcinoma: IntOGen driver in 3 cohorts (HCC)
- Colorectal cancer: CIViC evidence names this disease
- Renal cell carcinoma: IntOGen driver in 1 cohort (CHRCC)
- Breast cancer: Open Targets association 0.51 with breast cancer (MONDO_0007254)
- Retinoblastoma: CIViC evidence names this disease
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"CDKN1A" OR ABSTRACT:"CDKN1A" OR TITLE:"cyclin dependent kinase inhibitor 1A" OR ABSTRACT:"cyclin dependent kinase inhibitor 1A" OR TITLE:"Cyclin-dependent kinase inhibitor 1" OR ABSTRACT:"Cyclin-dependent kinase inhibitor 1" OR TITLE:"P21" OR ABSTRACT:"P21" OR TITLE:"CIP1" OR ABSTRACT:"CIP1" OR TITLE:"WAF1" OR ABSTRACT:"WAF1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDKN1A, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cdkn1a.json. Licence CC BY-NC 4.0.